To Evaluate the Safety, Tolerability and Pharmacokinetic of SAL0133 Tablets in Chinese Adult Healthy Subjects

Phase 1

Active, not recruiting

• Conditions: Pharmacokinetics
• Interventions: Drug: SAL0133; Drug: SAL0133 placebo

• Registration Number: NCT07030504
• Lead Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

Brief Summary

To evaluate the safety and tolerance of single and multiple administrations of SAL0133 tablets in adult healthy subjects in China receptivity.

Detailed Description

This study was divided into two parts: Part A and Part B. Part A was single-center, randomized, double-blind, and placebo control, single-dose escalation study (SAD) was conducted to evaluate the safety, tolerability and pharmacokinetic characteristics of SAL0133 tablets after a single dose. Furthermore, food effect would be preliminarily evaluated the influence of the pharmacokinetic characteristics of SAL0133 tablets in Part A. Part B was a single-center, randomized, double-blind, placebo controlled, multiple-dose escalation study was conducted to evaluate the safety, tolerability and pharmacokinetic characteristics of SAL0133 tablets after multiple doses.

Study Timeline

• Study Start: 2023-01-10
• Status Verified: 2025-06
• Primary Completion: 2025-06
• Study Completion: 2025-06-01
• Study First Submitted: 2025-06-10
• Study First Submitted QC: 2025-06-17
• Last Update Submitted: 2025-06-17
• Study First Posted: 2025-06-22
• Last Update Posted: 2025-06-22

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

• Participants have fully understood the trial's objectives, procedures, and potential adverse effects, and voluntarily signed informed consent form prior to the trial.
• Healthy male or female adults aged 18 to 65 years (inclusive).The gender ratio shall be no less than one third.
• Body weight ≥50 kg for male participants and ≥45 kg for female participants at screening, with a body mass index (BMI) between 19.0 and 26.0 kg/m2 (inclusive; BMI = body weight ÷ height2).
• No abnormalities or only slight abnormalities not clinically significant of tests/examinations (including physical examination, vital sign examination, blood routine, urine routine, blood biochemistry, coagulation function, five thyroid function tests, five pituitary function tests, serological virology, 12-lead electrocardiogram, normal chest position, abdominal B-ultrasound, etc) as judged by the investigator.
• The subject or their partner had no pregnancy plans during the study period and within one month after the last administration of the study drug, and the subjects do not donate sperm or eggs (oocytes, oocytes) for reproductive or assisted reproductive purposes.

Exclusion Criteria

• Pregnant or lactating women, or women of child-bearing potential (WOCBP) with a positive pregnancy test at screening.
• A history of clinically significant drug allergies or allergic diseases (such as asthma, urticaria, eczema).
• Dermatitis, etc., or as determined by the investigator, it may or is clear to be effective against the research drug (including similar drugs and controls) or allergy to the medicine and any of its excipients. Clinically significant underlying liver diseases or medical history, including chronic hepatitis B, chronic hepatitis C, and alcohol liver disease and metabolism-related fatty liver disease, etc.
• Fever symptom or active infection within one week before the first administration of the drug.
• Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) and/or the total bilirubin (TBIL) is higher than the upper limit of the normal value (ULN) during screening.
• Have undergone gastric surgery, vagotomy, intestinal resection or any other procedures that might interfere with the gastrointestinal tract surgical procedures for peristalsis, pH or absorption.
• Have received active or attenuated vaccines within 4 weeks before screening. ·Any of the following drugs or treatments were used before the first administration.
• Drug or drug abuse, alcohol abuse, smoking addiction or special diet, etc. Any one of the antibody results is positive: Hepatitis B surface antigen, hepatitis C antibody, Treponema pallidum antibody, human immunodeficiency virus (HIV).
• Have participated in clinical studies of other drugs and taken any clinical study drugs within 3 months prior to the screening.
• Who have donated blood or lost ≥400 mL of blood, received blood transfusion or used blood products within 3 months prior to the screening.
• There is any disease history or current illness that may affect the safety of the subjects or the in vivo process of the investigational drug, including but not limited to the central nervous system, cardiovascular system, digestive system, respiratory system and endocrine system, urinary system, blood system, immune system, psychiatry, metabolic disorders, and those who have undergone gastrointestinal surgery (Except for cauditis surgery), etc.
• History of fainting from needles or blood, and it has been judged by the researcher to be of clinical significance.
• Any other reason, the researcher determines that the subject is not suitable to participate in this study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
MAD 150mg Fed	SAL0133	6 subjects received active drug and 2 subjects received placebo once daily for seven days under fasting condition
MAD 150mg Fed	SAL0133 placebo	6 subjects received active drug and 2 subjects received placebo once daily for seven days under fasting condition
MAD 300mg Fed	SAL0133	6 subjects received active drug and 2 subjects received placebo once daily for seven days under fasting condition
MAD 300mg Fed	SAL0133 placebo	6 subjects received active drug and 2 subjects received placebo once daily for seven days under fasting condition
MAD 150mg Fasting	SAL0133 placebo	6 subjects received active drug and 2 subjects received placebo once daily for seven days under fasting condition
SAD 50mg Fasting	SAL0133	6 subjects received active drug and 2 subjects received placebo once daily under fasting condition
SAD 50mg Fasting	SAL0133 placebo	6 subjects received active drug and 2 subjects received placebo once daily under fasting condition
SAD 150mg Fasting	SAL0133	6 subjects received active drug and 2 subjects received placebo once daily under fasting condition
SAD 150mg Fasting	SAL0133 placebo	6 subjects received active drug and 2 subjects received placebo once daily under fasting condition
SAD 300mg Fasting	SAL0133	6 subjects received active drug and 2 subjects received placebo once daily under fasting condition
SAD 300mg Fasting	SAL0133 placebo	6 subjects received active drug and 2 subjects received placebo once daily under fasting condition
SAD 150mg Fed	SAL0133	6 subjects received active drug and 2 subjects received placebo once daily under fed condition
SAD 150mg Fed	SAL0133 placebo	6 subjects received active drug and 2 subjects received placebo once daily under fed condition
SAD 300mg Fed	SAL0133	6 subjects received active drug and 2 subjects received placebo once daily under fed condition
SAD 300mg Fed	SAL0133 placebo	6 subjects received active drug and 2 subjects received placebo once daily under fed condition
SAD 600mg Fed	SAL0133	6 subjects received active drug and 2 subjects received placebo once daily under fed condition
SAD 600mg Fed	SAL0133 placebo	6 subjects received active drug and 2 subjects received placebo once daily under fed condition
MAD 150mg Fasting	SAL0133	6 subjects received active drug and 2 subjects received placebo once daily for seven days under fasting condition

Primary Outcome Measures

Name	Time	Method
The rate of AE	from Day 1 to Day 5 or Day 10	The rate of AE occurred in the whole study
The rate of SAE	from Day 1 to Day 5 or Day 10	The rate of SAE occurred in the whole study
blood pressure	from Day 1 to Day 5 or Day 10	the change (mmHg) of blood pressure including SBP and DBP in the whole study

Trial Locations

Locations (1)

Shenzhen People's Hospital; 🇨🇳 Shenzhen, Guangdong, China